Protagonist Therapeutics Inc (PTGX)
Return on equity (ROE)
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 162,110 | -78,955 | -140,484 | -137,611 | -140,188 | -127,393 | -130,106 | -132,678 | -122,483 | -125,551 | -107,530 | -81,489 | -70,068 | -66,150 | -64,765 | -73,411 | -83,164 | -77,187 | -73,551 | -65,877 |
Total stockholders’ equity | US$ in thousands | 560,444 | 336,677 | 302,149 | 294,068 | 216,167 | 215,608 | 243,616 | 267,978 | 301,778 | 300,021 | 329,660 | 357,447 | 259,334 | 279,606 | 169,590 | 167,485 | 62,666 | 79,964 | 95,358 | 84,316 |
ROE | 28.93% | -23.45% | -46.49% | -46.80% | -64.85% | -59.09% | -53.41% | -49.51% | -40.59% | -41.85% | -32.62% | -22.80% | -27.02% | -23.66% | -38.19% | -43.83% | -132.71% | -96.53% | -77.13% | -78.13% |
March 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $162,110K ÷ $560,444K
= 28.93%
Protagonist Therapeutics Inc's Return on Equity (ROE) has shown significant fluctuations over the past 20 quarters. The most recent ROE of 28.93% as of March 31, 2024, indicates a strong return generated by the company for its shareholders. This is a positive sign as it shows the company's ability to generate profit from the shareholders' equity.
However, the company experienced negative ROE values in several quarters, with the lowest being -132.71% as of March 31, 2020. Negative ROE values can be a cause for concern as it indicates that the company is not effectively utilizing shareholder funds to generate profits.
The negative ROE values observed in the past could be attributed to various factors such as operational inefficiencies, high debt levels, or poor financial performance. It is important for Protagonist Therapeutics Inc to closely monitor its ROE and take necessary measures to improve profitability and efficiency in order to enhance shareholder value in the long run.
Peer comparison
Mar 31, 2024